Agenda for September 2026 Immunisation Advisory Committee (IAC) meeting
Information on what the Immunisation Advisory Committee (IAC) will be considering at its upcoming meeting in September 2026.
Matters arising
RSV Programme overview
The Committee will discuss the potential approach to an RSV immunisation programme in New Zealand.
All RSV related applications(external link)
Recombinant zoster vaccine (Shingrix) for immunocompromised people at increased risk of shingles
The Committee will discuss widening access to the recombinant zoster vaccine for immunocompromised people who are at increased risk of shingles and its complications. The Committee previously considered this topic at their March 2024 Immunisation Advisory Committee meeting(external link) and their June 2025 Immunisation Advisory Committee(external link). Further advice will be sought to confirm the eligibility criteria.
Application for recombinant zoster vaccine for immunocompromised people(external link)
Applications
Human Papillomavirus 9-valent vaccine (Gardasil 9) widened access
The Committee will discuss an application to widen access for the Human Papillomavirus 9-valent (HPV) vaccine for people living with HIV who are aged 9 – 45 years.
Application for Human Papillomavirus 9-valent vaccine for people with HIV(external link)
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.